Oral Mucositis Challenging the priorities of cancer therapy

Introduction

Oral mucositis is a common and debilitating side effect of cancer therapies that threatens the successful treatment of up to 600,000 people worldwide. Inexpensive treatments can sometimes alleviate mucositis, but a truly effective treatment has yet to be launched. 

Scope

An overview of the biological causes, epidemiology and risk factors associated with oral mucositis 

Analysis of the current treatment methods used for oral mucositis 

Analysis of the phase III drugs currently in development for oral mucositis 

Recommendations for the ideal mucositis treatment and market penetration strategies 

Report Highlights

Oral mucositis is one of the most debilitating side effects of cancer treatment that occurs in around 40% of cancer patients, representing a large patient population. There is a vast unmet need in the treatment of oral mucositis, as there is currently no effective treatment. 

Oral mucositis presents a commercial opportunity for a pharmaceutical company with the ideal treatment. 

Numerous routes of market penetration are available for a pharmaceutical company with a mucositis product 

Reasons to Purchase

Define the size or the oral mucositis market 

Identify a means of penetrating the oral mucositis market 

Understand the current treatment methods used for oral mucositis and see how your product fits in to the marketplace 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a251